which were confirmed to occur in cis and were inherited from an unaffected parent. The cis inherited from an unaffected carrier parent; these probands were also excluded. Three Thus, we identified 92 probands with confirmed recessive NOD2 variants within our (Table S1 , Figure S1 ). The majority of the compound heterozygous individuals (65/67) carry a function of NOD2 in the pathophysiology of CD (6). In total, 92 of 1,183 (7.8%) of the probands 1 5 6 in our pediatric onset IBD cohort conformed to a recessive, Mendelian inheritance mode for 1 5 7 NOD2 rare and low frequency (MAF<5%) deleterious variants (Table 1, Figure 1, Table S1 , and 1 5 8 Table S4 ). The 92 pediatric patients homozygous for NOD2 mutations were predominantly male 1 6 0 (71%) with a median age at diagnosis of 12.5 years (Table S1 ). At diagnosis, 83% displayed intestinal manifestations, mainly large joint arthritis, chronic recurrent multifocal osteomyelitis, 1 6 3 recurrent fevers, erythema nodosum, and pyoderma gangrenosum. Only 6% of the cohort 1 6 4 showed significant perianal disease (namely fistulae and abscesses, skin tags and fissures were not considered as perianal disease) (Table S1 ). Per the Montreal classification of IBD (45),
44% of the overall cohort of patients presented with ileal disease at diagnosis (L1). 25% presented with ileocolonic disease (L3) and 10% displayed features of colonic inflammation only 1 6 8 (L2). Isolated upper disease was only present in 2% of the cohort (L4). We observed a 1 6 9 progression of ileal disease in 21% (18.5% stricturing; 2.5% penetrating) with 21% requiring a 1 7 0 resection. On review of the Crohn's disease patients only, 50% displayed L1 disease (terminal
ileal +/-limited cecal disease), 32.9% L3 (ileocolonic) disease; 86.8% B1 (non-stricturing, non-1 7 2 penetrating) disease, 10.5% B2 (stricturing) disease (Table S1 ). Given the substantial contribution of recessive NOD2 variants to CD in our pediatric onset IBD cohort and the known contribution of NOD2 to adult CD, we next investigated the contribution of NOD2 recessivity in a large clinical population. For this, we examined a cohort of adult IBD patients from the RGC -Geisinger Health System (GHS) DiscovEHR study (46 2). We also observed instances of putative compound heterozygosity for each of the three main CD risk alleles along with either a rarer CD risk allele or a novel allele or two rare alleles in trans 1 9 4 (N=24), parallel to the findings in our pediatric IBD cohort. Using familial relationships and 1 9 5 pedigree reconstruction (47), we were able to confirm appropriate segregation for 32 of the 64
DiscovEHR recessive NOD2 variant carriers with IBD, including trans inheritance in 13 putative 1 9 7 compound heterozygotes ( Figure S2 ). The other 32 were singleton cases where phase could 1 9 8 not be confirmed. Overall, we identified 64 homozygous or putative compound heterozygous Table S4 ).
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We were also able to evaluate longitudinal de-identified medical records for all patients 5 were resolved as CD and 1 could not be defined; 16 compound heterozygotes exhibited a 2 0 8 conflicting diagnosis of CD of which 6 were resolved as CD and 10 were resolved as UC ( Table   2  0  9 S3). In total, we found that 17/18 (94.4%) of homozygous NOD2 individuals and 33/46 (71.7%) 2 1 0 compound heterozygous had a diagnosis of CD and that 9.9% of all CD cases in this cohort 2 1 1 could be attributed to homozygous or compound heterozygous variants in NOD2. We next 2 1 2 investigated age of disease onset using the first recorded date of an IBD diagnosis in the EHR. We identified 6 carriers of recessive NOD2 variants (9.4% of our recessive NOD2 patients with
IBD) who were diagnosed with IBD prior to 18 years of age. We also identified an additional 11
carriers of recessive NOD2 variants diagnosed with IBD prior to age 30 years, which is at or 2 1 6 below the average age of IBD diagnosis (48) and is consistent with earlier disease onset ( Table   2 1 7 S3). Of note, our RGC-GHS DiscovEHR data extends to a median of 14 years (and maximum of EHR by the Geisinger Health System. Since 72.4% of our cohort is currently over the age of 50 2 2 0 years, we cannot determine whether the age of onset for IBD occurred prior to the first 2 2 1 electronically recorded date of an IBD diagnosis for many recessive NOD2 patients; thus it is 2 2 2 possible that other individuals with homozygous or compound heterozygous variants in NOD2 2 2 3 might have had pediatric-onset disease that was not captured in the EHR. Finally, given the recessive inheritance of NOD2 variants observed in both our pediatric 2 2 5 onset and adult IBD cohorts, we estimated the disease risk for the three main known CD risk P-value 1.38X10 -12 ). We also calculated the effect sizes using a recessive model for these two 2 3 9
variants and the 22 compound heterozygotes carrying any combination of the 3 CD risk alleles.
We found that recessive effect sizes for the p.R702W and p.L1007fs variants were similar to Further, while we observe a low effect size for single allele carriers, based on our allelic 2 6 4 effect size calculations for each of the 3 main CD risk alleles in our DiscovEHR cohort (Table 3 ,
Figure 2), we hypothesize that homozygous and compound heterozygous NOD2 individuals
included in large IBD GWAS cohorts have likely contributed to a large proportion of the relative 2 6 7 risk calculations for IBD, specifically for CD, under additive models, and that homozygous effect conditional statistical analysis of these large and heterogeneous cohorts based on NOD2 2 7 0 genotypes may increase power to detect other loci that contribute to IBD. gene-environment exposures may further explain heterogeneity in onset and presentation of 2 9 0 disease for genetically-sensitized recessive NOD2 carriers.
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Given the wide variability in clinical presentation of IBD (54), we cannot exclude the 2 9 2 possibility that recessive NOD2 carriers exhibit subclinical phenotypes not formally diagnosed
as IBD or that they may eventually develop IBD. It is additionally possible that recessive NOD2 on this variable expressivity or incomplete capture of medical information. We also cannot 2 9 7
exclude the possibility that recessive NOD2 carriers possess additional genes or alleles that either contribute to disease onset and severity or, alternatively, provide protection or reduced 2 9 9 expressivity of the phenotype. Identification of these genetic modifiers warrants future and to identify protective genes and alleles that can be used to derive therapeutic avenues for 3 0 2
IBD treatment and management. In summary, in a cohort of 1,183 pediatric and early onset IBD patients, we report probands. We assessed the contribution of NOD2 recessive inheritance in a broader,
heterogeneous cohort of adult IBD patients, similar to those recruited for GWAS, and found that 3 0 7
recessive inheritance of variants in NOD2 account for 6.5% of these IBD patients, including defined subset of Crohn's disease patients. Materials and Methods:
We performed whole exome sequencing on a cohort of 1,183 probands with pediatric
onset IBD (ages 0-18.5 years), including their affected and unaffected parents and siblings,
where available (total samples = 2,704). All individuals were consented for genetic studies
under an IRB-approved protocol by the Toronto Hospital for Sick Children. Sample preparation,
whole exome sequencing, and sequence data production were performed at the Regeneron
Genetics Center (RGC) as previously described (46). In brief, 1ug of high-quality genomic DNA 3 2 4
for exome capture using the NimbleGen VCRome 2.1 design. Captured libraries were reads. Exome sequencing was performed such that >85% of the bases were covered at 20x or 3 2 7
greater. Raw sequence reads were mapped and aligned to the GRCh37/hg19 human genome
reference assembly, and called variants were annotated and analyzed using an RGC developed 3 2 9
pipeline. Briefly, variants were filtered based on their observed minor allele frequencies at a 3 3 0 <2% cutoff using the internal RGC database and other population control databases (ExAC (69) variants in consideration of disease prevalence. conflicts to disclose. Trust to study VEOIBD. cohorts; variants in red are predicted loss-of-function that result in nonsense mediated decay.
The three "common" low-frequency Crohn's Disease risk variants are highlighted: R702W outside of the 95% CI for the Composite genotypic homozygous and recessive models. Diamonds correspond to estimated OR values for these same variants in the IBD Exomes Browser (49); no confidence intervals are provided. 
